Furino Claudio, Grassi Maria Oliva, Bini Vito, Nacucchi Annalisa, Boscia Francesco, Reibaldi Michele, Recchimurzo Nicola, Alessio Giovanni
Eye Clinic, Azienda Ospedaliero-Universitaria Policlinico, University of Bari, Bari, Italy.
Eye Clinic, Department of Ophthalmology, University of Sassari, Sassari, Italy.
J Ophthalmol. 2020 Apr 15;2020:3680406. doi: 10.1155/2020/3680406. eCollection 2020.
To report the occurrence of endophthalmitis and other complications after intravitreal injections (IVIs) in the Arc Sterile setting.
A retrospective study that enrolled all patients who underwent IVIs between November 2017 and March 2019, collecting data about the patient's gender and age, type of injected drug, diagnosis, other ocular pathologies, physician and possible occurrence of endophthalmitis, or other complications.
Ten thousand and eighty-three IVIs were performed during the study period, involving 2014 eyes of 1,670 patients with an average age of 71.37 ± 11.63 years. The injected drugs included ranibizumab (54.6%), aflibercept (38.0%), dexamethasone (6.7%), pegaptanib (0.3%), bevacizumab (0.4%), and ocriplasmin (0.01%). The diagnosis included neovascular age-related macular degeneration (859), myopic choroidal neovascularization (154), diabetic macular edema (576), retinal vein occlusion (203), and miscellaneus diagnosis (222). No cases of endophthalmitis were recorded. One hundred and sixty-nine cases of ocular hypertension were detected, while the most frequent complication was subconjunctival hemorrhage, identified after 1,180 IVIs. The residents performed over 80% of IVIs, but there was no statistically significant difference in incidence of complications between the residents group and consultants group.
Arc Sterile seems to be a safe setting in which IVIs can be carried out, regarding infective risk, and it is easy to set up compared to operation theatre and useful to improve intravitreal injections governance.
报告在无菌环境下玻璃体内注射（IVI）后眼内炎及其他并发症的发生情况。
一项回顾性研究，纳入了2017年11月至2019年3月期间接受IVI的所有患者，收集患者的性别、年龄、注射药物类型、诊断、其他眼部病变、医生以及眼内炎或其他并发症可能发生情况的数据。
研究期间共进行了10083次IVI，涉及1670例患者的2014只眼，平均年龄为71.37±11.63岁。注射药物包括雷珠单抗（54.6%）、阿柏西普（38.0%）、地塞米松（6.7%）、哌加他尼（0.3%）、贝伐单抗（0.4%）和奥克纤溶酶（0.01%）。诊断包括新生血管性年龄相关性黄斑变性（859例）、近视性脉络膜新生血管（154例）、糖尿病性黄斑水肿（576例）、视网膜静脉阻塞（203例）和其他杂项诊断（222例）。未记录到眼内炎病例。检测到169例高眼压病例，而最常见的并发症是结膜下出血，在1180次IVI后发现。住院医师进行了超过80%的IVI，但住院医师组和会诊医师组之间并发症发生率无统计学显著差异。
就感染风险而言，无菌环境似乎是一个可进行IVI的安全环境，与手术室相比易于设置，并且有助于改善玻璃体内注射管理。
